NAUT — Nautilus Biotechnology, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1808805 ·
Last close
$2.36
Market Cap
$300.60M
52W High
$4.31
52W Low
$0.84
ADV30
8,683,148
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 10,000 | -5,000 | -15,763,000 | -14,469,000 | 163,576,000 | 13,166,000 | 32,464,000 |
| Mar 2026 | 0 | — | -16,124,000 | -14,697,000 | 177,779,000 | 14,626,000 | 33,364,000 |
| Dec 2025 | 0 | — | -15,424,000 | -13,781,000 | 191,112,000 | 12,388,000 | 34,139,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-52,482,000
Investing CF
$37,480,000
Financing CF
$1,476,000
CapEx
$-2,653,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.46
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-376,822,000
Inventory
—
Receivables
—
ST Investments
$76,109,000
EBIT TTM
$-64,048,000
Pretax Income TTM
$-58,583,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$424,000
EBITDA
$-62,759,000
Free Cash Flow
$-31,660,000
Enterprise Value
$287,891,712
Total Cash
$86,576,000
Total Debt
$26,741,000
Shares Out
127,372,425
Trailing EPS
$-0.46
Book Value
$0.92
ROE
-41.0%
ROA
-22.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -66,837,000 | -59,001,000 | 191,112,000 | 34,139,000 | 156,973,000 | -50,696,000 |
| Dec 2024 | 0 | -81,476,000 | -70,780,000 | 242,743,000 | 34,013,000 | 208,730,000 | -59,145,000 |
| Dec 2023 | 0 | -76,152,000 | -63,675,000 | 305,565,000 | 40,212,000 | 265,353,000 | -51,711,000 |
| Dec 2022 | 0 | -63,618,000 | -57,924,000 | 350,052,000 | 35,128,000 | 314,924,000 | -45,806,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
$-56,521,000
OpCashFlow TTM
—
Assets (Latest)
$163,576,000
Forward EPS
$-0.74
Max Pain — expiry 2027-03-19
max pain strike: $2.00 · spot: $2.43 · call oi: 8,547 · put oi: 475
Expected Move to 2027-03-19:
±$1.65
(67.90%) —
implied range
$0.78 –
$4.08
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PMTS | CPI Card Group Inc. | $300.87M | $25.86 | — |
| MNTN | MNTN, Inc. | $299.93M | $4.77 | — |
| EFR | Eaton Vance Senior Floating-Rate Trust | $301.44M | $10.21 | — |
| GOTU | Gaotu Techedu Inc. | $298.98M | $2.39 | — |
| RMIX | Suncrete, Inc. | $298.50M | $6.05 | — |
News headlines (Yahoo Finance, 1h cache)
Nautilus: 3 Key Takeaways for Long-Term Investors
2026-11-05 18:50 · Yahoo
Nautilus Biotechnology, Inc. Q3 2026 Earnings Call Summary
2026-10-27 17:40 · Yahoo
Nautilus (NAUT) Q3 2026 Earnings Call Transcript
2026-10-27 17:29 · Yahoo
Nautilus Biotechnology Q3 Earnings Call Highlights
2026-10-27 15:05 · Yahoo
Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
2026-10-27 10:00 · Yahoo
Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium
2026-10-27 10:00 · Yahoo
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
2026-10-15 12:00 · Yahoo
Nautilus Biotechnology Q2 Earnings Call Highlights
2026-07-28 14:04 · Yahoo
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
2026-07-28 12:00 · Yahoo
Nautilus Biotechnology (NASDAQ:NAUT) Is In A Good Position To Deliver On Growth Plans
2026-05-05 11:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.